Avacta Group (AVCT) Share Price, News & Analysis

Company Overview

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Key Stats

• Today's Range: 45.53 to 49
• 50-Day Range: 43 to 64.60
• 52-Week Range: 39.63 to 119.90
• Volume: 614,136 shs
• Average Volume: 2.27 million shs
• Market Capitalization: £171.09 million
• P/E Ratio: N/A
• Dividend Yield: 3.97%
• Price Target: N/A
• Consensus Rating: N/A

AVCT Stock Analysis - Frequently Asked Questions

How have AVCT shares performed this year?

Avacta Group's stock was trading at GBX 116.50 at the start of the year. Since then, AVCT shares have decreased by 59.0% and is now trading at GBX 47.75.
View the best growth stocks for 2024 here.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) released its earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share for the quarter. Avacta Group had a negative net margin of 114.45% and a negative trailing twelve-month return on equity of 73.02%.

How do I buy shares of Avacta Group?

Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avacta Group investors own include Legal & General Group (LGEN), Lloyds Banking Group (LLOY), Lloyds Banking Group (LYG), IQE (IQE), Barclays (BARC), Meta Platforms (META) and Revvity (PKI).

Company Calendar

• Last Earnings: 9/28/2020
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:AVCT
• CUSIP: N/A
• CIK: N/A
• Web: www.avacta.com
• Phone: +44-1904-217070
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-25,890,000.00
• Net Margins: -114.45%
• Pretax Margin: N/A
• Return on Equity: -73.02%
• Return on Assets: -21.80%

Debt

• Debt-to-Equity Ratio: 63.54
• Current Ratio: 1.29
• Quick Ratio: 4.96

Sales & Book Value

• Annual Sales: £22.62 million
• Price / Sales: 7.56
• Cash Flow: GBX 3.18 per share
• Price / Cash Flow: 15.00
• Book Value: GBX 14 per share
• Price / Book: 3.41

Miscellaneous

• Outstanding Shares: 358,300,000
• Free Float: N/A
• Market Cap: £171.09 million
• Optionable: Not Optionable
• Beta: 1.12